drugset / Trial / NCT05342792
Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma
Phase 3
Recruiting
556 enrolled
Sun Yat-sen University
Affiliated Cancer Hospital of Guizhou Medical University · collabCancer Hospital of Guangxi Medical University · collabChongqing University Cancer Hospital · collabFifth Affiliated Hospital, Sun Yat-Sen University · collabFirst People's Hospital of Foshan · collabHubei Cancer Hospital · collabHunan Cancer Hospital · collabShandong Provincial Hospital · collabThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · collabTongji Hospital · collabUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · collabXiangya Hospital of Central South University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This trial is aimed to investigate whether additional adjuvant PD-1 antibody treatment could improve survival in high-risk nasopharyngeal carcinoma compared to metronomic capecitabine alone.
Timeline
- Start
- 2022-04-17
- Primary completion
- 2027-06
- Completion
- 2029-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Capecitabine | Small molecule | 650 mg/m2 | Oral |